What Miami-Dade residents need to know as county faces $402 million deficit
The mayor said there are no proposed service cuts to Metrorail, Metrobus or Metromover, but fares for Metrorail and Metrobus will rise by 50 cents. The current $2.25 fare will increase to $2.75 beginning Oct. 1.
"It's kind of bizarre for us to have to pay that much to be able to move around," Jose Carlos Ponce, a Metrobus rider, told CBS News Miami.
Ponce said he began using the service a month ago while searching for a job.
Levine Cava said the county will maintain its historically low property tax rate and does not anticipate a millage increase. However, cuts will be made to offset the deficit.
"In [Miami-Dade] Parks, some programming will be reduced," the mayor said, adding that the specific programs affected will depend on whether a park offers amenities such as pools or sports activities.
The Office of New Americans, which provides services for immigrants in the county, is also among the agencies facing cuts.
Levine Cava said the Miami-Dade Sheriff's Office requested a 14% budget increase for next year, but her proposal includes an 8.5% increase.
County commissioners are scheduled to discuss the proposed budget on Wednesday. Public comments will be taken in September before a final version is approved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Elliott Statement on Southwest Governance Changes
WEST PALM BEACH, Fla. , July 31, 2025 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott") today released the following statement on behalf of Partner John Pike and Portfolio Manager Bobby Xu regarding Rakesh Gangwal's decision to step down from his role as Chair at Southwest Airlines Co. (NYSE: LUV) (the "Company" or "Southwest"): We thank Mr. Gangwal for his leadership and contributions as Southwest's independent Chair during a transformational period for the company and we are grateful that he will continue to serve as a member of the Board. We remain confident in Southwest's trajectory and we look forward to continuing our constructive engagement as the Company executes its plan to drive long-term value. About Elliott Elliott Investment Management L.P. (together with its affiliates, "Elliott") manages approximately $72.7 billion of assets as of December 31, 2024. Founded in 1977, it is one of the oldest funds under continuous management. The Elliott funds' investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm. Media Contact: Casey Friedman Elliott Investment Management L.P. (212) 478-1780 cfriedman@ View original content to download multimedia: SOURCE Elliott Investment Management L.P. Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
Investors react to Trump's new reciprocal tariffs announcement
SINGAPORE (Reuters) -President Donald Trump signed an executive order on Thursday imposing reciprocal tariffs ranging from 10% to 41% on U.S. imports from dozens of countries and foreign locations. Rates were set at 25% for India's U.S.-bound exports, 20% for Taiwan's and 30% for South Africa's. Trump also signed an executive order on Thursday increasing tariffs on Canadian goods to 35% from 25%, the White House said. QUOTES: TONY SYCAMORE, MARKET ANALYST, IG, SYDNEY: "At this point, the reaction in markets has been modest, and I think part of the reason for that is the recent trade deals with the EU, Japan, and South Korea have certainly helped to cushion the impact, as has Mexico being granted a 90-day reprieve. And Trump said that trade talks with China are doing reasonably well there. "So on top of all of that, you have the TACO trade type situation whereby, after being obviously caught on the wrong foot in April, the market now, I think, has probably taken the view that these trade tariff levels can be renegotiated, can be walked lower over the course of time." BRIAN JACOBSEN, CHIEF ECONOMIST, ANNEX WEALTH MANAGEMENT, MENOMONEE FALLS, WISCONSIN (emailed comment): "Just because we now have clarity on the tariffs, that doesn't mean we have certainty about their effects. "There are those who think that tariff-induced consumer price inflation will slowly build as businesses work down inventories and test how strong their pricing power is. Others think the tariff-induced inflation will peak earlier, showing up mostly in crimped profit margins and resulting in slower growth. "However, what tariffs take with one hand, maybe tax incentives to invest and more open foreign markets can give with the other hand."
Yahoo
14 minutes ago
- Yahoo
Trump doubles down on Most Favored Nation plan to target drug prices
US President Donald Trump has called on pharmaceutical manufacturers to lower US drug prices in line with the Most Favored Nation (MFN) policy first proposed in an executive order in May. On 31 July, the White House said letters were sent to leading pharmaceutical manufacturers like AstraZeneca, AbbVie, Eli Lilly, Regeneron, Novartis, Pfizer, and more, calling on them to take steps to lower drug prices in the US such that they match the lowest prices in other developed countries within the next 60 days. President Trump also shared many of these letters on the social media platform Truth Social. While this is not the first time the administration has floated the MFN policy, this time, the language used to address pharma companies is more aggressive. If the companies do not comply, the order states, the federal government 'will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices.' In response to this statement, a spokesperson for the industry body BIO said, 'We share the Administration's goal of ending foreign freeloading on American innovation. But importing socialist price controls would lead only to fewer new medicines and the rationing of healthcare for Americans and would strengthen and embolden foreign adversaries whose goal is to dominate the world in biotechnology.' The BIO spokesperson said eliminating the middlemen, ending the abuse of drug reimbursement programs like 340B would be a way to simplify the system, protect patients and narrow the pricing gap between the US and other developed countries. 'Middlemen' or pharmacy benefit managers (PBMs) are often blamed by the pharmaceutical companies for high drug prices. PBMs on their part have said they negotiate with different stakeholders to drive down costs, and pass on savings obtained through rebates and discounts to health plans. The letter to the manufacturers implores them to provide drug at 'MFN rates' to all Medicaid patients, and commit to providing these prices for newly launched drugs to all major US buyers like Medicare and commercial plans. The latest announcement also calls on drug manufacturers to opt in for platforms where drugs can be sold directly to patients at prices that are comparable to those in developed nations, which are currently offered to third party payers. Among the letters posted on Truth Social, Trump directly called on several CEOs like Albert Bourla of Pfizer, and Leonard Schleifer of Regeneron, by using their first names instead of a formal address. Several countries use international reference pricing as a strategy in their health systems. However, chief among the criticism following the May executive order has been the lack of details. Industry experts have highlighted a lack of clarity on how any potential list price changes will affect the prices patients pay at the pharmacy counter given the complex dynamics and multiple stakeholders in the US healthcare system. There is also a concern that if the US implements reference pricing, it could influence when companies choose to launch drugs in certain ex-US markets to avoid those potentially lower prices from being used as references. Furthermore, pharma companies have chosen the litigation route to fight legislative changes targeting drug prices, like the Inflation Reduction Act, and the same could be seen with the MFN executive order, as per a Bank of America report. "Trump doubles down on Most Favored Nation plan to target drug prices" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. 登入存取你的投資組合
